7. Chemotherapeutic inroads in treating stage iv non-small cell lung cancer

Current Problems in Cancer

Volumn 20, Issue 4, 1996, Pages 221-246

  Langer, Corey J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33749116549     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (116)

1. Boring C, Squires T, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994:44:7-26.
2. Lanzotti VJ, Thomas DR. Boyle LE. et al. Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer 1977:39:303-13.
3. Minna JD, Pass H. Clalstcin E, et al. Cancer of the lung. In: DeVita V, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott, 1989:591-705.
4. Klastersky J, Scullier J. Bureau G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989:7:1087-92.
5. Kis MG, Cralla PJ, Kelson DP, et al. Trial of vindesine plus mitomycin in stage III (AJCC stage IV) non-small cell lung cancer. An active out-patient regimen. Chest 1985:87:368-72.
6. Klatesky J. Therapy of non-small cell lung cancer. Lung Cancer 1995;12 Suppl 1:8133-45.
7. Kawahara M, Furese K, Kodama N, Yamamoto M, Kubota K, Takada M, et al. A randomized study of cisplatin versus cisplatin plus vindesine for nonsmall cell lung cancer. Cancer 1991;88:714-9.
8. Cartel G, Cartel F, Cantone A, et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care vs supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 1993;85:794-800.
9. Rapp E, Pater JL, William A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer. Report of a Canadian multi-center randomized trial. J Clin Oncol 1988;6:633-41.
10. Ruckdeschel JC, Finkelstein DM, Mason BA, et al. Chemotherapy for metastatic non-small bronchogenic carcinoma: EST 2575, generation V-A randomized comparison of four cisplatin containing regimens. J Clin Oncol 1985;3:72-9.
11. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
12. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Group study. J Clin Oncol 1986;4:702-9.
13. Sines RJ. Risk-benefit relationship in cancer trials: the ECOG experience in non-small cell lung cancer. J Clin Oncol 1985;3:462-72.
14. Johnson DH. Semin Oncol 1990;17 Suppl 7
15. Shepherd FA. Future directions in the treatment of non-small cell lung cancer. Semin Oncol 1994;21:48-62.
16. Jaakimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E. Counting the costs of chemotherapy: a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol;8: 1301-9.
17. Donnadieu N, Paesmans M, Sculier JR Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer 1991;7:243-52.
18. Grilli R, Oxman A, Julian J. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993:11:1866-72.
19. Gralla RJ, Casper B, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating dosage schedules. Ann Intern Med 1981;95:414-20.
20. Gandara D, Crowley J, Livingston RB, et al. Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993:11:873-8.
21. Klastersky J, Sculier J, Ravez P, et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of non-small cell lung cancer. J Clin Oncol 1986;4:1780-6.
22. Bunn CA. Clinical experiences with carboplatin in lung cancer. Semin Oncol 1992;19 Suppl 2:1-11.
23. Green MR, Kreisman H, Lickart S, et al. Carboplatin in non-small cell lung cancers: the Cancer and Leukemia Group B experience. In: Bunn PA Jr, Canetta R, Ozols R, et al, editors. Carboplatin (JM-9): current perspectives and future directions. Philadelphia: Saunders, 1990:301-6.
24. Bonomi PD, Finkelstein PM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer. A study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-13.
25. Klasterskey J, Sculier J-R Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990:8:1556-62.
26. Pommier Y. Topoisomerase inhibitors: why do they work? Why do they fail? Proc Am Assoc Cancer Res 1993:34:567.
27. Slichenmyer Wf, Rowinsky EK, Donehower R, et al. The current status of camptothecin analogues as anti-tumor agents. J Natl Cancer Inst 1993;85:27191.
28. Burris HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992;84:1816-20.
29. Burris HA, Rothenberg ML, Kühn JG, et al. Clinical trials with topoisomerase I inhibitors. Semin Oncol 1992;19:663-9.
30. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologie study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
31. Burris H, Kühn J, Wall J, el al. Early clinical trials of topotecan, a new topoisomerase I inhibitor [abstract]. Ann Oncol 1992;3 Suppl 1:118.
32. Verweij J, Lund B, Beynen J, et al. Clinical study with topotecan: the EORTC experience [abstract]. Ann Oncol 1992;3 Suppl 1:118.
33. Wall JG, Burris HA III, Von Hoff DD, et al. A phase I clinical and pharmacokinetic study of the topoisomerase inhibitor topotecan (SKF 104864) given as an intravenous bolus every 2 days. Anticancer Drugs 1992;3:337-45.
34. Lynch TJ, Kalish L, Strauss C, et al. Phase II study of topotecan in metastatic non-small cell lung cancer. J Clin Oncol 1994:12:347-52.
35. Perez-Soler R, Glisson BB, Kane J, et al. Phase II study of topotecan in patients with non-small cell lung cancer previously untreated [abstract 1223]. Proc Am Soc Clin Oncol 1994:13
36. Weitz JJ, Jung S-H, Marschke RF Jr, et al. Randomized Phase II trial of 2 schedules of topotecan for the treatment of advanced stage non-small cell lung cancer: an NCCTG trial [abstract 1053], Proc Am Soc Clin Oncol 1995:14
37. Fukuoka M, Niitani H, Susuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer. J Clin Oncol 1992:10:16-20.
38. Negora S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 1991:83:1164-8.
39. Nakai H, Fukuoka M, Furuse K, et al. An early phase II study of CPT-11 in primary lung cancer. Jpn J Cancer Chemother 1991:18:607-12.
40. Itoh K, Takada M, Kudo S, et al. Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines demonstrated by computer analysis [abstract]. Lung Cancer 1991 ;7 Suppl:124.
41. Kudoh S, Takada M, Masuda N, et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 1993:84:203-7.
42. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, et al. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 1992:10:1775-80.
43. MasudaN, FukuokaM, Kudoh S, Kusunoki Y, Matsui K, TakifujiN, et al. Phase I and pharmacologie study of irinotecan in combination with cisplatin in advanced lung cancer. Br J Cancer 1993;68:777-82.
44. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 1994;12:90-6.
45. Boven E, Erkelens CA, Pinedo HM, et al. The new cytidine analog gemcitabine (GEM) has schedule-rather than dose-related activity in human tumor xenografts [abstract 2270]. Proc Am Assoc Cancer Res 1991;32
46. Anderson H, Lund B, Hansen HH, et al. Phase II study of gemcitabine in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1991 ;10: 247.
47. Anderson H, Lund B, Bach F, et al. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821-6.
48. Abratt R, Bexwoda W, Falkson G, et al. Efficacy and safety of gemcitabine in non-small cell lung cancer: phase I study results [abstract]. Proc Am Soc Clin Oncol 1992;11:311.
49. Abratt RP, Bexwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a Phase II study. J Clin Oncol 1994;12:1535-40.
50. Shepard FA, Gatzemeier V, Golfried M, et al. An extended phase II study of gemcitabine in non-small cell lung cancer [abstract 1096]. Proc Am Soc Clin Oncol 1993:12:330.
51. Fossella E Lippman S, Pang A. et al. Phase I/II study of gemcitabine by 30 minute weekly intravenous infusion x 3 weeks every 4 weeks for non-small cell lung cancer [abstract 1082]. Proc Am Soc Clin Oncol 1993;12:336.
52. Negoro S, Fukuoka M, Kurita Y, et al. Results of phase II studies of gemcitabine in non-small cell lung cancer [abstract 1239]. Proc Am Soc Clin Oncol 1994;13
53. Fossella FV, Lippman S. Pang A, et al. Phase I/II study of gemcitabine (G) by 30 minute weekly I.V. infusion x 3 weeks every 4 weeks for non-small cell lung cancer (NSCLC) [abstract 1082]. Proc Am Soc Clin Oncol 1993;12.
54. Steward WP, Dunlop DJ, Cameron DC, Talbot JR et al. Phase I/II study of cisplatin in combination with gemcitabine in non-small cell lung cancer (NSCLC) [abstract 1064]. Proc Am Soc Clin Oncol 1995;14
55. Abratt RP, Bexwoda WR, Goedhals L, Hacking DJ. A phase II study of gemcitabine with cisplatin in patients with non-small cell lung cancer [abstract 1159]. Proc Am Soc Clin Oncol 1995;14
56. Crino L, Scagliotti G, Marangolo M, Figoli F, Cleroci M, et al. Cisplatingemcitabine combination in non-small cell lung cancer (NSCLC) [abstract 1066]. Proc Am Soc Clin Oncol 1995;14
57. Sandler AB, Ansari R, McLean J, Fisher W, Dorr A, Einhorn LH. A Hoosier Oncology Group Phase II study of gemcitabine plus cisplatin in non-small cell lung cancer [abstract 1089]. Proc Am Soc Clin Oncol 1995;14
58. Shepherd E Cormier Y, Burkes R, et al. Phase I study of gemcitabine and cisplatin for advanced non-small cell lung cancer [abstract 422]. Lung Cancer 1994;11 Suppl 1:116.
59. Shepherd FA, Cormier Y, Binkes R, Crump M, et al. Modified continual reassessment methodology (MCRM): a superior way to assess toxicity in a phase I study of gemcitabine and cisplatin for non-small cell lung cancer [abstract 1090]. Proc Am Soc Clin Oncol 1995;14
60. Binet S, Chaineau E, Fellou A, et al. Immunofluorescence study of the action of navelbine. vincristine and vinblastine on mitotic and axonal microtubules. Int I Cancer 1990:46:262-6.
61. Fellou S, Chayan R, Vacassin T, et al. Biochemical effects of navalbine on tnbulin and associated proteins. Semin Oncol 1989:16 Suppl 4:9-14.
62. Depierre A, Lomarie E, Dabouis G, et al. Efficacy of navelbine (NVB) in non-small cell lung cancer. Semin Oncol 1989;16:33-6.
63. Depierre A, Lemarie E, Dabouis G, Gamier G. Jacoulet P, Dalphin JC. A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer." Am J Clin Oncol 1991:14:115-9.
64. Yokoyama A. Furuse K, Niitani H, et al. Multi-institutional Phase II study of navelbine (vinorelbine) in non-small cell lung cancer [abstract]. Proc Am Soc Glin Oncol 1992:11:287.
65. O'Rourke M, Crawford J, Schiller J, et al. Survival advantage for patients with stage IV NSCLC treated with single agent navelbine in a randomized controlled trial [abstract]. Proc Am Soc Clin Oncol 1993;12:343.
66. LeChevalier T. Brisgand D, Douillard JT, et al. Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin vs vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994:12:360-7.
67. Paul M, Gueria JC, Kleisbauer JP, et al. Multicenter randomized trial comparing cisplatin-mitomycin-vindesine vs cisplatin-mitomycin-navelbine in advanced non-small cell lung cancer [abstract 434]. Lung Cancer 1994;11 Suppl 1:114.
68. SWOG 9308 phase III randomized trial of cisplatin alone versus combined cisplatin and vinorelbine in advanced NSCLC.
69. 68a. Wozniak A, Crowley J, Baker S, étal. Randomized phase III trial of cisplatin vs cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: report of SWOG 9308. Proc Am Soc Clin Oncol 1996;15:A-1110.
70. Sirotnak FM, DeGraw JI, Moccio FA, et al. New folate analogs of the 10-deazoaminopterin series as basis for structural design and biochemical and pharmacologie properties. Cancer Chemother Pharmacol 1984;12:18-25.
71. Sirotnak FM, DeGraw JI, Schmid FA, et al. New folate analogs of the 10deazo-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in asitic and solid murine tumor models. Cancer Chemother Pharmacol 1984:12:26-30.
72. Schmid FA, Sirotnak FM, Otter GM, et al. New antifolate analogs of the 10deazo-aminopterin series. Markedly increased activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 1985:69:551-3.
73. Shum KY, Kris MG, Gralla RJ, et al. Phase II study of 10-ethyl-lO-deazoaminoprotein in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1988:6:446-50.
74. Souhami RL, Rudd RM, Spiro SG, et al. Phase II study of edatrexate in stage III and IV non-small cell lung cancer. Cancer Chemother Pharmacol 1992:30:465-8.
75. Lee JS, Libschitz HI, Murphy WK, et al. Phase II study of 10-ethyl-lO-deazoaminopterin (10-EDAM; CGP 30694) for stage IIIB or IV non-small cell lung cancer. Invest New Drugs 1990:8:299-304.
76. Lee JS, Libshitz HI, Murphy WK, et al. Phase II study of 10-ethyl-lO-deazoaminopterin for stage IIIB or IV non-small cell lung cancer. Proc Am Soc Clin Oncol 1991:10:299-304.
77. Souhami R, Hartley J, Alien R, et al. Phase II study of 10-ethyl-lO-deazo-aminopterin in untreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1991;10:252.
78. Kris MG, Gralla RJ, Potanovich LM, et al. Incorporating 10-ethyl-lO-deazoaminopterin (EDAM) into combination therapy with mitomycin and vinblastine for patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1989;8:227.
79. Comis R, Kris MG, Lee JS, et al. Multicenter randomized trials in 673 comparing the combination of edatrexate, mitomycin, and vinblastine (EMV) with mitomycin and vinblastine in patients with stage IV and IIIB non-small cell lung cancer [abstract 455]. Lung Cancer 1994;11 Suppl 1:119.
80. Rigas JR, Pfister DG, Miller VA, et al. Combination trials of edatrexate with paclitaxel or cisplatin in patients with advanced non-small cell lung cancer [abstract 479]. Lung Cancer 1994;11 Suppl 1:125.
81. Lee JS, Libschitz HI, Fossella FR, et al. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide and cisplatin regimen for nonsmall cell lung cancer. J Natl Cancer Inst 1992;84:1039-40.
82. Pisters KMW, Tyson LB, Bertino JR, et al. Phase I and pharmacokinetic study of high dose edatrexate (EDX) with oral leucovorin in adults with solid Proc Am Soc Clin Oncol 1993;12:163.
83. Gueritte-Voegelein E Guenard D, Lavelle E et al. Relationship between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991;34:992-8.
84. Schiff PB, Fant J, HorwitzSB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
85. Choy H, Rodriguez FE Koester SM, et al. Investigation of taxol as a potential radiation sensitizer. Cancer 1983;71:3774-8.
86. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994:86:441-6.
87. Burris H. Eckardt J, Fields S, et al. Phase II trials of taxotere in patients with non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1993;12: 335.
88. Cerny T, Wanders J, Kaplan S, et al. Taxotere is an active drug in non-small cell lung cancer: a phase II trial of the early clinical trials group [abstract]. Proc Am Soc Clin Oncol 1993;12:331.
89. Francis P, Rigas J, Kris M, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994:12:1232-7.
90. Fossella E Lee J, Murphy W, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994;12:1238-44.
91. Fossella FV Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995;13:645-61.
92. Watanabe KJ, Yokoyama A, Furuse K, et al. Phase II trial of docetaxel in previously treated non-small cell lung cancer [abstract 1095]. Proc Am Soc Clin Oncol 1994;13
93. Zalcberg J, Bishop J, Millward MJ, et al. Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer [abstract 1062]. Proc Am Soc Clin Oncol 1995;14
94. Cole JT, Gralla RJ, Marques CB, Rittenberg CN. Phase MI study of cisplatin and docetaxel in non-small cell lung cancer [abstract 1087]. Proc Am Soc Clin Oncol 1995;14
95. LeChevalier T, Belli L, Monnier A. Phase II study of docetaxel and cisplatin in advanced non-small coll lung cancer [abstract|. Proc Am Soc Clin Oncol 1995:14:1059.
96. Chang AY, Kim K, Click J, el al. Phase II Study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Croup Expérience. J Natl Cancer Inst 1993;85: 388-94.
97. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer, j Natl Cancer Inst 1993:85:384-8.
98. Catzemeier U, Pawel JV, Heckmayer M, et al. Phase II study with paclitaxel in advanced inoperable non-small cell lung cancer (NSCLC): the European experience [abstract]. Lung Cancer 1994;11 Suppl 2:246.
99. Tester W, Cohn I, Desai A, et al. Phase II study of short infusion paclitaxel in patients with stage IV non-small cell lung cancer [abstract 1189], Proc Am Soc Clin Oncol 1995;14
100. Hainsworth JD. Creco A. Paclitaxel administered by 1-hour infusion. Cancer 1994:74:1377-82.
101. Hainsworth JD, Raefsky E, Creco A. Paclitaxel administered by a 1-hour infusion: a phase I-II trial comparing two schedules. Cancer J Sci Am 1005:1:281-7.
102. Hainsworth JD. Thompson D, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastalic non-small cell lung cancer. J Clin Oncol 1995:13:1609-14.
103. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: phase II toxicity, response and survival analysis. J Clin Oncol 1995;13:1860-70.
104. Egorin MJ, VanEcho DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the ci's-diammine-dichloroplatinum(II) analogue diammine cyclobutane-dicarboxylatoplatinum. Cancer Res 1995:45:6502-6.
105. Calvert AH. Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
106. Ozols RE Kilpatrick D, O'Dwyer P, et al. Phase I and pharmacokinetic study of taxol and carboplatin in previously untreated patients with advanced epithelial ovarian cancer: a pilot study of the Gynecologic Oncology Group [abstract]. Proc Am Soc Clin Oncol 1993:12:250.
107. Johnson DH, Paul DM, Hände KR, DeVore RE Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial LUN-46. Semin Oncol 1995:22 Suppl 9:30-3.
108. Paul D, DeVore RD, Hande K, Stewart S, Murphy B, Blanke C, et al. Phase II trial of carboplatin and paclitaxel in advanced non-small cell lung cancer [abstract 1103]. Proc Am Soc Clin Oncol 1995;14
109. Israel VK, Zaretskv S, Natale RB. Phase I/II trial of combination carboplatin and taxol in advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1994:13:351.
110. Kelly K, Bunn PA Jr. Phase I trials of taxol containing chemotherapy regimens for the treatment of advanced non-small cell (NSCLC) and small cell lung cancer (SCLC) [abstract 468]. Lung Cancer 1994;11:122.
111. Giaccone C, Huizing M, Postmus P ten Bokkel, Huinink WW, et al. Dose finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 1995;22 Suppl 9:78-82.
112. Rowinsky E. Sartorius SE, Bowling MK, et al. Paclitaxel as a 3-hour schedule and carboplatin in non-small cell lung cancer: use of maximally tolerated and clinically relevant single agent doses in combination is feasible [abstract 1075]. Proc Am Soc Clin Oncol 1995;14:
113. Belani C, Aisner J, Hiponia D, Engstrom C. Paclitaxel and carboplatin with or without filgastrim support in patients with metastatic non-small cell lung cancer. Semin Oncol 1995;22 Suppl 9:7-12.
114. Georgiadis NS, Russell E, Johnson BE. Prolonging the exposure of human lung cancer cell lines to paclitaxel increases the cytotoxicity [abstract]. Lung Cancer 1994;11 Suppl 1:5.
115. Georgiadis NS, Brown JE, Schuler BS, Frame JN, Johnson PE. Phase I study of a four day continuous infusion of paclitaxel followed by cisplatin in patients with advanced lung cancer [abstract 1092]. Proc Am Soc Clin Oncol 1995:14
116. Bononi P, Kim K, Chang A, Johnson D. Phase III trial comparing etopisidecisplatin versus taxol-cisplatin-G-CSF versus taxol-cisplatin in advanced non-small cell lung cancer: an ECOG trial. Proc Am Soc Clin Oncol 1996;15: 1145.